McGlynn Margaret G

SEC CIK: 0001215126

SEC filings (opens in a new tab)

No open-market purchases or sales filed in the past year.

Current role at each company

NVAX Novavax IncDirectoras of Jun 23, 2026
FOLD Amicus Therapeutics, Inc.Directoras of Apr 27, 2026
VRTX Vertex Pharmaceuticals IncDirectoras of May 3, 2023

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought: –; 0 filings
Sold: –; 0 filings
Net: –; Bought minus sold
Companies: 0; With open-market trades

Trades

Every Form 4 that lists McGlynn Margaret G as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Transaction type

Role

Minimum value (USD)

Filed from

Filed to

Filing delay at least (days)

Filing delay at most (days)

FOLD Amicus Therapeutics, Inc.

Director3 trades

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Mar 6, 2024 (view filing)	Mar 4-5	2 days	McGlynn Margaret GDirector	SSale	−15.0K	$13.35	−$200.2K	−20.2%59.3K after	2 lots10b5-1
Jan 17, 2023 (view filing)	Jan 13	4 days	McGlynn Margaret GDirector	SSale	−15.0K	$13.03	−$195.4K	−22.8%50.7K after
May 4, 2022 (view filing)	May 2	2 days	McGlynn Margaret GDirector	SSale	−15.0K	$6.99	−$104.8K	−28.3%38.0K after

VRTX Vertex Pharmaceuticals Inc